Sanofi Completes Acquisition of Dynavax for $2.2 Billion
Sanofi has completed its acquisition of Dynavax, adding its adult vaccines and pipeline candidates to strengthen Sanofi’s presence in adult immunization.
Sanofi has successfully completed its acquisition of Dynavax Technologies Corporation, marking a significant step forward in bolstering its adult immunization portfolio. This move brings together Dynavax's innovative vaccines—including a marketed adult hepatitis B vaccine distinguished by its efficient two-dose regimen—with Sanofi's extensive global reach, commercial infrastructure, and R&D capabilities. The deal positions Sanofi to accelerate advancements in adult vaccines, addressing key public health needs with greater speed and scale.
"Dynavax enhances Sanofi's adult immunization presence by adding differentiated vaccines that complement Sanofi's expertise," said Thomas Triomphe, Executive Vice President, Vaccines, Sanofi.
"Joining Sanofi will provide the global scale and expertise needed to maximize the impact of our vaccine portfolio," said Ryan Spencer, Chief Executive Officer, Dynavax.
The transaction concluded seamlessly, with the tender offer for Dynavax shares expiring on February 9, 2026, and Sanofi accepting all validly tendered shares at $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion. Dynavax has now merged into a Sanofi subsidiary, becoming an indirect wholly owned entity, and its common stock ceased trading on NASDAQ as of February 10, 2026.
